Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Miedzynarodowy Instytut Biologii Molekularnej I Komorkowej W Warszawie currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, LOUNTOS, GEORGE THEMISTOCLIS. The prosecution is located within 1 distinct art unit, which indicates a specific technical focus for the company's current intellectual property efforts. This structure means that the practitioner's interactions are limited to a centralized point of contact for all current filings at the patent office.
The busiest examiner identified in the data is LOUNTOS, GEORGE THEMISTOCLIS, who holds 1 busiest examiner pending action. This count represents the entirety of the institute's current pending workload. Because the portfolio involves only the identified examiner and art unit in its pending cases, the strategy does not currently require managing multiple procedural standards. The 1 pending office action in Biotechnology & Pharmaceuticals serves as the primary focal point for the institute's near-term patent acquisition goals at the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LOUNTOS, GEORGE THEMISTOCLIS | 1 | 57.1% | +60.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17768608 | RECOMBINANT POLYPEPTIDE FOR USE AS A MEDICINE, ANTISEPTIC AGENT, ANTIBACTERIAL AGENT, ANTI-INFLAMMATORY AGENT, COMPOSITIONS COMPRISING IT AND USES THEREOF | LOUNTOS, GEORGE THEMISTOCLIS | 63d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17768608 | RECOMBINANT POLYPEPTIDE FOR USE AS A MEDICINE, ANTISEPTIC AGENT, ANTIBACTERIAL AGENT, ANTI-INFLAMMATORY AGENT, COMPOSITIONS COMPRISING IT AND USES THEREOF | LOUNTOS, GEORGE THEMISTOCLIS | 63d |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17768608 | RECOMBINANT POLYPEPTIDE FOR USE AS A MEDICINE, ANTISEPTIC AGENT, ANTIBACTERIAL AGENT, ANTI-INFLAMMATORY AGENT, COMPOSITIONS COMPRISING IT AND USES THEREOF | LOUNTOS, GEORGE THEMISTOCLIS | 1652 | §103§112 | Final Rejection | 63d | Pending | Apr 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial